Vision outcomes using a port delivery system proved equivalent to ranibizumab injections and showed a positive benefit profile, according to data presented at the virtual American Academy of Ophthalmology annual meeting.
These findings suggest that continuous delivery of ranibizumab by the port delivery system (PDS) could reduce treatment burden in patients with neovascular age-related macular degeneration (nAMD).
The PDS was designed to distribute an intravitreal delivery of ranibizumab via a surgical implant in the pars plana and refill exchanges.
“The primary objective was to evaluate
Uncategorized